About
Immunotherapy
Areas of Focus
Categories
Biologics & Biopharmaceutical
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
8
As Collaborator
3
Total Enrollment
1,330
By Phase
PHASE3: 2PHASE1/PHASE2: 2PHASE2: 3PHASE1: 4
By Status
COMPLETED: 4ACTIVE_NOT_RECRUITING: 3RECRUITING: 2UNKNOWN: 1TERMINATED: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06472245Lead Sponsor
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
PHASE3Recruiting
363 participants
Started: Dec 3, 2024 · Completed: Dec 15, 2028
NCT05751798Lead Sponsor
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
PHASE1/PHASE2Recruiting
41 participants
Started: Dec 20, 2022 · Completed: Dec 31, 2029
NCT04713514Collaborator
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
PHASE2Active, not recruiting
180 participants
Started: Aug 5, 2021 · Completed: Dec 31, 2025
NCT04837092Collaborator
Phase I/II Study of FR104 First Administration in Patient with Renal Transplantation: FIRsT Study
PHASE1/PHASE2Active, not recruiting
10 participants
Started: Jun 28, 2021 · Completed: Mar 31, 2025
NCT04885361Lead Sponsor
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
PHASE1Unknown
48 participants
Started: May 26, 2021 · Completed: Mar 31, 2022
Locations (1)
Headquarters
Nantes, France
Map
Loading map...